BioRestorative Therapies (BRTX) Revenue & Revenue Breakdown
BioRestorative Therapies Revenue Highlights
Latest Revenue (Y)
$145.80K
Latest Revenue (Q)
$233.60K
BioRestorative Therapies Revenue by Period
BioRestorative Therapies Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $145.80K | 21.70% |
| 2022-12-31 | $119.80K | 160.43% |
| 2021-12-31 | $46.00K | -40.26% |
| 2020-12-31 | $77.00K | -40.77% |
| 2019-12-31 | $130.00K | 17.12% |
| 2018-12-31 | $111.00K | 37.04% |
| 2017-12-31 | $81.00K | 122.80% |
| 2016-12-31 | $36.35K | -94.22% |
| 2015-12-31 | $628.91K | 51.18% |
| 2014-12-31 | $416.00K | 24661.67% |
| 2013-12-31 | $1.68K | -89.22% |
| 2012-12-31 | $15.59K | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2010-12-31 | - | - |
BioRestorative Therapies generated $145.80K in revenue during NA 2023, up 21.70% compared to the previous quarter, and up 131.35% compared to the same period a year ago.
BioRestorative Therapies Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | $233.60K | 162.18% |
| 2024-06-30 | $89.10K | 154.57% |
| 2024-03-31 | $35.00K | 81.35% |
| 2023-12-31 | $19.30K | -37.13% |
| 2023-09-30 | $30.70K | -52.40% |
| 2023-06-30 | $64.50K | 106.07% |
| 2023-03-31 | $31.30K | 745.95% |
| 2022-12-31 | $3.70K | -87.24% |
| 2022-09-30 | $29.00K | -59.21% |
| 2022-06-30 | $71.10K | 344.38% |
| 2022-03-31 | $16.00K | 220.00% |
| 2021-12-31 | $5.00K | -37.50% |
| 2021-09-30 | $8.00K | -46.67% |
| 2021-06-30 | $15.00K | -16.67% |
| 2021-03-31 | $18.00K | 5.88% |
| 2020-12-31 | $17.00K | 13.33% |
| 2020-09-30 | $15.00K | -21.05% |
| 2020-06-30 | $19.00K | -26.92% |
| 2020-03-31 | $26.00K | -18.75% |
| 2019-12-31 | $32.00K | -15.79% |
| 2019-09-30 | $38.00K | 22.58% |
| 2019-06-30 | $31.00K | 6.90% |
| 2019-03-31 | $29.00K | - |
| 2018-12-31 | $29.00K | 11.54% |
| 2018-09-30 | $26.00K | -29.73% |
| 2018-06-30 | $37.00K | 94.74% |
| 2018-03-31 | $19.00K | -50.00% |
| 2017-12-31 | $38.00K | 137.50% |
| 2017-09-30 | $16.00K | -20.00% |
| 2017-06-30 | $20.00K | 185.71% |
| 2017-03-31 | $7.00K | 15.23% |
| 2016-12-31 | $6.08K | 21.50% |
| 2016-09-30 | $5.00K | -69.05% |
| 2016-06-30 | $16.16K | 77.04% |
| 2016-03-31 | $9.13K | -95.42% |
| 2015-12-31 | $199.13K | 107.16% |
| 2015-09-30 | $96.12K | -35.39% |
| 2015-06-30 | $148.76K | -19.54% |
| 2015-03-31 | $184.90K | 131.85% |
| 2014-12-31 | $79.75K | -50.13% |
| 2014-09-30 | $159.93K | -9.10% |
| 2014-06-30 | $175.94K | 46817.60% |
| 2014-03-31 | $375.00 | 100.00% |
| 2013-12-31 | - | -100.00% |
| 2013-09-30 | $125.00 | -70.59% |
| 2013-06-30 | $425.00 | -62.39% |
| 2013-03-31 | $1.13K | 210.44% |
| 2012-12-31 | $364.00 | -93.03% |
| 2012-09-30 | $5.22K | -47.75% |
| 2012-06-30 | $10.00K | 100.00% |
| 2012-03-31 | - | 100.00% |
| 2011-12-31 | - | 100.00% |
| 2011-09-30 | - | 100.00% |
| 2011-06-30 | - | 100.00% |
| 2011-03-31 | - | 100.00% |
| 2010-12-31 | - | 100.00% |
| 2010-09-30 | - | - |
BioRestorative Therapies generated $233.60K in revenue during Q3 2024, up 162.18% compared to the previous quarter, and up 362.17% compared to the same period a year ago.
BioRestorative Therapies Revenue Breakdown
BioRestorative Therapies Revenue Breakdown by Product
Quarterly Revenue by Product
| Product/Service | Sep 24 | Jun 24 |
|---|---|---|
| Royalty | $2.90K | $19.80K |
| Product | $230.70K | $69.30K |
Latest
BioRestorative Therapies's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: Product (98.76%), and Royalty (1.24%).
BioRestorative Therapies Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| CAPR | Capricor Therapeutics | $25.18M | $2.26B |
| PULM | Pulmatrix | $7.30M | $366.00K |
| SABS | SAB Biotherapeutics | $2.24M | $263.14K |
| BRTX | BioRestorative Therapies | $145.80K | $233.60K |
| ANEB | Anebulo Pharmaceuticals | - | - |
| SLNO | Soleno Therapeutics | - | - |
| BPTH | Bio-Path | - | - |
| XTLB | XTL Biopharmaceuticals | - | - |
| CING | Cingulate | - | - |
| AKTX | Akari Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| MNPR | Monopar Therapeutics | - | - |
| CADL | Candel Therapeutics | - | - |
| ACHV | Achieve Life Sciences | - | - |